Case 18-10518-KG Doc 511 Filed 07/12/18 Page 1 of 2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: OREXIGEN THERAPEUTICS, INC., Debtor. 1 Chapter 11 Case No. 18-10518 (KG) Re: D.I. 459 NOTICE OF FILING OF REVISED EXHIBIT B TO OMNIBUS MOTION FOR ENTRY OF AN ORDER (I) AUTHORIZING THE DEBTOR TO REJECT CERTAIN CONTRACTS AND (II) GRANTING CERTAIN RELATED RELIEF PLEASE TAKE NOTICE that on July 3, 2018, the above-captioned Debtor filed and served the Omnibus Motion for Entry of an Order (I) Authorizing the Debtor to Reject Certain Contracts and (II) Granting Certain Related Relief (D.I. 459) (the Rejection Motion ). PLEASE TAKE FURTHER NOTICE that attached hereto as Exhibit A is a revised proposed order (the Revised Proposed Order ), which provides that certain of the Contracts 2 listed on Exhibit B to the Revised Proposed Order shall be rejected as of July 31, 2018. PLEASE TAKE FURTHER NOTICE that attached hereto as Exhibit B is a blackline version of the Revised Proposed Order as compared with the version of the proposed order attached as Exhibit B to the Rejection Motion. 1 The last four digits of the Debtor s federal tax identification number are 8822. The Debtor s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037. 2 Motion. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Rejection
Case 18-10518-KG Doc 511 Filed 07/12/18 Page 2 of 2 Dated: July 12, 2018 Wilmington, Delaware MORRIS, NICHOLS, ARSHT & TUNNELL LLP /s/ Tamara K. Mann Robert J. Dehney (No. 3578) Andrew R. Remming (No. 5120) Tamara K. Mann (No. 5643) 1201 N. Market St., 16th Floor P.O. Box 1347 Wilmington, DE 19899-1347 Telephone: (302) 658-9200 Facsimile: (302) 658-3989 rdehney@mnat.com aremming@mnat.com tmann@mnat.com - and - Christopher R. Donoho, III (admitted pro hac vice) Christopher R. Bryant (admitted pro hac vice) John D. Beck (admitted pro hac vice) HOGAN LOVELLS US LLP 875 Third Avenue New York, NY 10022 Telephone: (212) 918-3000 Facsimile: (212) 918-3100 chris.donoho@hoganlovells.com christopher.bryant@hoganlovells.com john.beck@hoganlovells.com Counsel for Debtor and Debtor in Possession
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 1 of 9 EXHIBIT A
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 2 of 9 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: OREXIGEN THERAPEUTICS, INC., Debtor. 1 Chapter 11 Case No. 18-10518 (KG) RE: D.I. OMNIBUS ORDER (I) AUTHORIZING THE DEBTOR TO REJECT CERTAIN CONTRACTS (II) GRANTING CERTAIN RELATED RELIEF This matter coming before the Court on the Omnibus Motion for Entry of an Order (I) Authorizing the Debtor to Reject Certain Contracts and (II) Granting Certain Related Relief (the Motion ) 2 filed by the above-captioned debtor and debtor in possession (the Debtor ); the Court having reviewed the Motion; the Court having found that (i) the Court has jurisdiction over this matter pursuant to 28 U.S.C. 157 and 1334 and the Amended Standing Order of Reference from the United States District Court for the District of Delaware, dated February 29, 2012, (ii) venue is proper in this district pursuant to 28 U.S.C. 1408 and 1409, (ii) this is a core proceeding pursuant to 28 U.S.C. 157(b), (iv) that this Court may enter a final order consistent with Article III of the United States Constitution; and (v) notice of the Motion and the Hearing was sufficient under the circumstances; after due deliberation the Court having determined that the relief requested in the Motion is necessary and essential for the administration of the Debtor s estate and such relief is in the best interests of the Debtor, its estate and its creditors; and good and sufficient cause having been shown; IT IS HEREBY ORDERED THAT: 1 The last four digits of the Debtor s federal tax identification number are 8822. The Debtor s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA 92037. 2 Capitalized terms not defined herein are defined in the Motion. 1
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 3 of 9 1. The Motion is GRANTED; 2. Pursuant to sections 105(a) and 365(a) of the Bankruptcy Code, the Contracts listed on Exhibit A hereto are hereby rejected by the Debtor, effective as of July 13, 2018; 3. Pursuant to sections 105(a) and 365(a) of the Bankruptcy Code, the Contracts listed on Exhibit B hereto are hereby rejected by the Debtor, effective as of July 31, 2018; 4. Notwithstanding the relief granted herein and any actions taken hereunder, nothing in the Motion or this Order shall: (i) constitute an admission as to the validity or priority of any claim against the Debtor; (ii) constitute a waiver of the Debtor s rights to dispute any claim; or (iii) prejudice the Debtor s rights to assert that any of the Contracts are not executory or unexpired within the meaning of section 365 of the Bankruptcy Code; enforceable upon its entry; 5. The terms and conditions of this order shall be immediately effective and 6. The rejection of the Contracts complies with the requirements of Bankruptcy Rule 6006(f); and 7. This Court shall retain jurisdiction to hear and determine all matters arising from or related to the implementation of this order. Dated:, 2018 Wilmington, Delaware THE HONORABLE KEVIN GROSS UNITED STATES BANKRUPTCY JUDGE 2
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 4 of 9 Exhibit A
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 5 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Abelson-Taylor, Inc. 33 West Monroe Street Suite 600 Chicago, IL 60603 Master Service Agreement 6/16/2016 Abelson-Taylor, Inc. 33 West Monroe Street Suite 600 Chicago, IL 60603 Work Order No. 1-2016 6/16/2016 Analytical Support for Zonisamide and Bupropion Combination 1/5/2005 Analytical Support for Zonisamide and Bupropion Combination 12/20/2004 Blackstone Group Agreement to acquire Cardinal Health letter 1/25/2007 Consultancy of Richard Soltero and Pharma Directions letter 3/8/2016 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 3/22/2005 Stability Study of Zonisamide CR and Bupropion SR Product for Orexigen 10/5/2005 Cardinal Health DSP - Amendment 1 1/1/2018 Cardinal Health Wholesale Purchase Agreement - Amendment 1 1/1/2018 Cardinal Health Wholesale Purchase Agreement 5/2/2016 Payment Agreement relating to Exclusive Distribution Agreement 1/12/2018 Payment Agreement relating to Exclusive Distribution Agreement 1/12/2018 Trade Power of Attorney 2/1/2012 Title Model Addendum to Exclusive Distribution Agreement 7/19/2016 Letter re: Amendment to the Exclusive Distribution Agreement Amendment to Title Model Addendum Between Orexigen Therapeutics, Inc. and Cardinal Health 105, Inc. 8/15/2016 12/20/2016 Quality Agreement Between Orexigen Therapeutics, Inc. And Cardinal Health 105, Inc. 9/1/2016 Exhibit A Statement of Work Between Orexigen Therapeutics, Inc. ("Client) And Cardinal Health 105, Inc. 8/16/2016 ("Cardinal Health") Title Model Addendum 7/19/2016 Exhibit A Statement of Work Between Orexigen Therapeutics, Inc. ("Client) And Cardinal Health 105, Inc. 8/16/2016 ("Cardinal Health") Development of IR Pellets of Naltrexone 4/13/2005 Development of IR Pellets of Naltrexone, Bupropion, Fluoxetine, and Zonisamide for Encapsulation of a 6/8/2004 Combination product and Clinical Manufacturing Preformulation Evaluation of Naltrexone 2/9/2015 Quotation Amendment for Development and Clinical Supplies Manufacturing of IR Naltrexone Pellets 6/9/2005 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 7/25/2005
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 6 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 12/14/2004 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 9/20/2005 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 10/26/2005 Development and Clinical Supplies Manufacturing of IR Naltrexone Pellets 1/11/2005 Development of IR Pellets of Naltrexone, Bupropion, Fluoxetine, and Zonisamide for Encapsulation of a 5/10/2004 inventiv Clinical Solutions 15915 Katy Freeway Suite 100 Houston, TX 77095 Budget Proposal for Orexigen Contrave Program Completed Appendices 14 & 16 for NB-301 (n=1742) 5/7/2016 inventiv Clinical Solutions, LLC 15915 Katy Freeway Suite 100 Houston, TX 77095 Smith Hanley Consulting Group Master Services Agreement for Contract Consulting Services 1/29/2009 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 re: Termination of Master Services Agreement 9/2/2010 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Exhibit A Time and Materials Work Agreement 3/30/2010 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Budget Proposal for Orexigen - Obesity Program 5/7/2016 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Services Agreement 10/16/2017 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 First Amendment to Project Agreement (Detailed) 5/2/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 First Amendment to Project Agreement (Sales, MMS and HAS Operations Support) 12/29/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Master Services Agreement 4/29/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Sales, MMS and HAS Operations Support) 6/30/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Tele-Detailing) 6/30/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Detailing) 5/2/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Statement of Work Ore 12828 3/11/2011 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Work Order (Start-Up Services) 3/28/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Letter re: Master Services Agreement dated as of April 29, 2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Work Order (Start-Up Services - Hardware) 4/1/2016 12/1/2017 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Notice to Reduce Sales Representatives 12/1/2017 8045 Arco Corporate Drive Suite inventiv Health Research & Insights 200 Raleigh, NC 27617 Statement of Work 8/23/2016 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Work Order 1/1/2018 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Statement of Work 1/1/2018 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Statement of Work 12/13/2017 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Service Agreement 1/20/2005
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 7 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Services Agreement 6/16/2004 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Addendum A-1 Statement of Work 1/14/2017 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Statement of Work 7/14/2004 McKesson Corporation 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 Core Distribution Agreement 7/1/2016 McKesson Patient Relationship 4343 North Scottsdale Road Suite First Amendment to Schedule of Services for Solutions, a business unit of Scottsdale, AZ 85251-3329 1/8/2017 370 Loyaltyscript Program for Contrave McKesson Specialty Arizona Inc. McKesson Patient Relationship Solutions, a business unit of McKesson Specialty Arizona Inc. 4343 North Scottsdale Road Suite 370 Scottsdale, AZ 85251-3329 Master Service Agreement 7/15/2016 McKesson Specialty Arizona, Inc. 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 First Amendment Master Services Agreement 9/23/2016 McKesson Specialty Arizona, Inc. 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 Second Amendment Master Services Agreement 1/20/2017
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 8 of 9 Exhibit B
Case 18-10518-KG Doc 511-1 Filed 07/12/18 Page 9 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Facebook, Inc. 15161 Collections Center Drive Chicago, IL 60693 Terms of Service 12/1/2017 Google, Inc. 7 Times Square, Suite 2900 New York, NY 10036-6524 Terms of Service N/A Microsoft (Bing) Online 6100 Neil Road Reno, NV 89511 Microsoft Bing Ads Agreement 12/1/2017
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 1 of 9 EXHIBIT B BLACKLINE
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 2 of 9 I. IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 OREXIGEN THERAPEUTICS, INC., Debtor. 1 Case No. 18-10518 (KG) RE: D.I. OMNIBUS ORDER (I) AUTHORIZING THE DEBTOR TO REJECT CERTAIN CONTRACTS (II) GRANTING CERTAIN RELATED RELIEF This matter coming before the Court on the Omnibus Motion for Entry of an Order (I) Authorizing the Debtor to Reject Certain Contracts and (II) Granting Certain Related Relief (the Motion ) 2 filed by the above-captioned debtor and debtor in possession (the Debtor ); the Court having reviewed the Motion; the Court having found that (i) the Court has jurisdiction over this matter pursuant to 28 U.S.C. 157 and 1334 and the Amended Standing Order of Reference from the United States District Court for the District of Delaware, dated February 29, 2012, (ii) venue is proper in this district pursuant to 28 U.S.C. 1408 and 1409, (ii) this is a core proceeding pursuant to 28 U.S.C. 157(b), (iv) that this Court may enter a final order consistent with Article III of the United States Constitution; and (v) notice of the Motion and the Hearing was sufficient under the circumstances; after due deliberation the Court having determined that the relief requested in the Motion is necessary and essential for the administration of the Debtor s estate and such relief is in the best interests of the Debtor, its estate and its creditors; and good and sufficient cause having been shown; IT IS HEREBY ORDERED THAT: 1. The Motion is GRANTED; 1 The last four digits of the Debtor s federal tax identification number are 8822. The Debtor s mailing address for purp oses of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA 92037. 2 Capitalized terms not defined herein are defined in the Motion. 1
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 3 of 9 2. Pursuant to sections 105(a) and 365(a) of the Bankruptcy Code, the Contracts listed on Exhibit A hereto are hereby rejected by the Debtor, effective as of July 13, 2018; 3. Pursuant to sections 105(a) and 365(a) of the Bankruptcy Code, the Contracts listed on Exhibit B hereto are hereby rejected by the Debtor, effective as of July 31, 2018; 4. 3. Notwithstanding the relief granted herein and any actions taken hereunder, nothing in the Motion or this Order shall: (i) constitute an admission as to the validity or priority of any claim against the Debtor; (ii) constitute a waiver of the Debtor s rights to dispute any claim; or (iii) prejudice the Debtor s rights to assert that any of the Contracts are not executory or unexpired within the meaning of section 365 of the Bankruptcy Code; 5. 4. The terms and conditions of this order shall be immediately effective and enforceable upon its entry; 6. 5. The rejection of the Contracts complies with the requirements of Bankruptcy Rule 6006(f); and 7. 6. This Court shall retain jurisdiction to hear and determine all matters arising from or related to the implementation of this order. Dated:, 2018 Wilmington, Delaware THE HONORABLE KEVIN GROSS UNITED STATES BANKRUPTCY JUDGE 2
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 4 of 9 Exhibit A
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 5 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Abelson-Taylor, Inc. 33 West Monroe Street Suite 600 Chicago, IL 60603 Master Service Agreement 6/16/2016 Abelson-Taylor, Inc. 33 West Monroe Street Suite 600 Chicago, IL 60603 Work Order No. 1-2016 6/16/2016 Analytical Support for Zonisamide and Bupropion Combination 1/5/2005 Analytical Support for Zonisamide and Bupropion Combination 12/20/2004 Blackstone Group Agreement to acquire Cardinal Health letter 1/25/2007 Consultancy of Richard Soltero and Pharma Directions letter 3/8/2016 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 3/22/2005 Stability Study of Zonisamide CR and Bupropion SR Product for Orexigen 10/5/2005 Cardinal Health DSP - Amendment 1 1/1/2018 Cardinal Health Wholesale Purchase Agreement - Amendment 1 1/1/2018 Cardinal Health Wholesale Purchase Agreement 5/2/2016 Payment Agreement relating to Exclusive Distribution Agreement 1/12/2018 Payment Agreement relating to Exclusive Distribution Agreement 1/12/2018 Trade Power of Attorney 2/1/2012 Title Model Addendum to Exclusive Distribution Agreement 7/19/2016 Letter re: Amendment to the Exclusive Distribution Agreement Amendment to Title Model Addendum Between Orexigen Therapeutics, Inc. and Cardinal Health 105, Inc. 8/15/2016 12/20/2016 Quality Agreement Between Orexigen Therapeutics, Inc. And Cardinal Health 105, Inc. 9/1/2016 Exhibit A Statement of Work Between Orexigen Therapeutics, Inc. ("Client) And Cardinal Health 105, Inc. 8/16/2016 ("Cardinal Health") Title Model Addendum 7/19/2016 Exhibit A Statement of Work Between Orexigen Therapeutics, Inc. ("Client) And Cardinal Health 105, Inc. 8/16/2016 ("Cardinal Health") Development of IR Pellets of Naltrexone 4/13/2005 Development of IR Pellets of Naltrexone, Bupropion, Fluoxetine, and Zonisamide for Encapsulation of a 6/8/2004 Combination product and Clinical Manufacturing Preformulation Evaluation of Naltrexone 2/9/2015 Quotation Amendment for Development and Clinical Supplies Manufacturing of IR Naltrexone Pellets 6/9/2005 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 7/25/2005
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 6 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 12/14/2004 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 9/20/2005 Quotation Amendment for Development of IR Pellets of Bupropion and Zonisamide for Encapsulation of a 10/26/2005 Development and Clinical Supplies Manufacturing of IR Naltrexone Pellets 1/11/2005 Development of IR Pellets of Naltrexone, Bupropion, Fluoxetine, and Zonisamide for Encapsulation of a 5/10/2004 inventiv Clinical Solutions 15915 Katy Freeway Suite 100 Houston, TX 77095 Budget Proposal for Orexigen Contrave Program Completed Appendices 14 & 16 for NB-301 (n=1742) 5/7/2016 inventiv Clinical Solutions, LLC 15915 Katy Freeway Suite 100 Houston, TX 77095 Smith Hanley Consulting Group Master Services Agreement for Contract Consulting Services 1/29/2009 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 re: Termination of Master Services Agreement 9/2/2010 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Exhibit A Time and Materials Work Agreement 3/30/2010 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Budget Proposal for Orexigen - Obesity Program 5/7/2016 inventiv Clinical Solutions, LLC 224 Schilling Circle Suite 160 Hunt Valley, MD 21031 Services Agreement 10/16/2017 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 First Amendment to Project Agreement (Detailed) 5/2/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 First Amendment to Project Agreement (Sales, MMS and HAS Operations Support) 12/29/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Master Services Agreement 4/29/2016 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Sales, MMS and HAS Operations Support) 6/30/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Tele-Detailing) 6/30/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Project Agreement (Detailing) 5/2/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Statement of Work Ore 12828 3/11/2011 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Work Order (Start-Up Services) 3/28/2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Letter re: Master Services Agreement dated as of April 29, 2016 inventiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Work Order (Start-Up Services - Hardware) 4/1/2016 12/1/2017 InVentiv Commercial Services, LLC 500 Atrium Drive Somerset, NJ 08873 Notice to Reduce Sales Representatives 12/1/2017 8045 Arco Corporate Drive Suite inventiv Health Research & Insights 200 Raleigh, NC 27617 Statement of Work 8/23/2016 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Work Order 1/1/2018 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Statement of Work 1/1/2018 IQVIA, Inc. P.O. Box 8500-784290 Philadelphia, PA 19178-4290 Statement of Work 12/13/2017 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Service Agreement 1/20/2005
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 7 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Services Agreement 6/16/2004 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Addendum A-1 Statement of Work 1/14/2017 McKesson BioServices Corporation 14655 Rothgeb Drive Rockville, MD 208050 Statement of Work 7/14/2004 McKesson Corporation 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 Core Distribution Agreement 7/1/2016 McKesson Patient Relationship 4343 North Scottsdale Road Suite First Amendment to Schedule of Services for Solutions, a business unit of Scottsdale, AZ 85251-3329 1/8/2017 370 Loyaltyscript Program for Contrave McKesson Specialty Arizona Inc. McKesson Patient Relationship Solutions, a business unit of McKesson Specialty Arizona Inc. 4343 North Scottsdale Road Suite 370 Scottsdale, AZ 85251-3329 Master Service Agreement 7/15/2016 McKesson Specialty Arizona, Inc. 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 First Amendment Master Services Agreement 9/23/2016 McKesson Specialty Arizona, Inc. 4343 North Scottsdale Road Scottsdale, AZ 85251-3329 Second Amendment Master Services Agreement 1/20/2017
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 8 of 9 Exhibit B
Case 18-10518-KG Doc 511-2 Filed 07/12/18 Page 9 of 9 Schedule of Orexigen Therapeutics, Inc. Contracts and Leases Counterparty Counterparty Address Counterparty City, State, Zip Lease / Contract Title Lease / Contract Effective Date Facebook, Inc. 15161 Collections Center Drive Chicago, IL 60693 Terms of Service 12/1/2017 Google, Inc. 7 Times Square, Suite 2900 New York, NY 10036-6524 Terms of Service N/A Microsoft (Bing) Online 6100 Neil Road Reno, NV 89511 Microsoft Bing Ads Agreement 12/1/2017